Simultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer
Journal of Clinical Investigation · 15.05.2026 · 136 (10)
DOI: 10.1172/jci190121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.05.2026. Verfasst von Selina Shiqing K Teh und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, DNA Breaks, Double-Stranded, CRISPR-Cas Systems. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes of Health, The Sol Goldman Pancreatic Cancer Research Center, PanCan/AACR Innovation Award.
Abstract (Originalsprache)
While radiation is an effective oncologic therapy, killing cancer by inducing DNA double-strand breaks (DSBs), it lacks specificity for neoplastic cells. We have previously adapted the CRISPR/Cas9 gene-editing technology as a cancer-specific treatment modality targeting somatic mutations in pancreatic cancer (PC). However, its tumoricidal potential remains unclear, especially in comparison with therapeutic doses of radiation. Here, we demonstrate that CRISPR/Cas9-induced DSBs are more cytotoxic in PCs than a comparable number of radiation-induced DSBs. We observed more than 90% tumor growth inhibition by targeting 9 sites with cancer-specific sgRNAs. Through both bioinformatics and cytogenetics analyses, we found that CRISPR/Cas9-induced DSBs triggered ongoing chromosomal rearrangements, with 87% of structural variants not directly produced from the initial CRISPR/Cas9-induced DSBs, and chromosomal instability peaking before cell death. By comparing the cytotoxicity of CRISPR/Cas9- and radiation-induced DSBs, we demonstrated that the number of DSBs required to achieve equitoxic effects was approximately 3 times higher for radiation than CRISPR/Cas9. Finally, we showed that PC cells that had survived CRISPR/Cas9 targeting retained susceptibility to subsequent CRISPR/Cas9-induced DSBs at different genomic sites with more than 87% growth inhibition. Together, our data support the therapeutic potential of CRISPR/Cas9 as an anticancer strategy. The CRISPR-Cas9 system can be adapted into a cancer killing strategy by inducing precise and unrecoverable DNA damage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center.
- Department of Radiation Oncology and Molecular Radiation Sciences; and.
- Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Förderung
- National Institutes of Health
- The Sol Goldman Pancreatic Cancer Research Center
- PanCan/AACR Innovation Award
- The STRINGER Foundation
- Casimir H. Zgonina Family Endowment for Pancreatic Cancer Research
- Dennis Troper and Susan Wojcicki
- Dick Knox/Cliff Minor Fund
- Edward A. Goldsmith Pancreatic Cancer Research Fund
Zitieren
APA
Teh, S. S. K., Kotwal, A., Bennett, A., Halper-Stromberg, E., Morsberger, L., Zamani, S., Shi, Y., Skaist, A., Zhu, Q., Bowland, K., Liang, H., Hruban, R. H., Hung, C. F., Anders, R. A., Roberts, N. J., Scharpf, R. B., Goldstein, M., Zou, Y. S., & Eshleman, J. R. (2026). Simultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer. Journal of Clinical Investigation, 136(10). https://doi.org/10.1172/jci190121
Vancouver
Teh SSK, Kotwal A, Bennett A, Halper-Stromberg E, Morsberger L, Zamani S, et al. Simultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer. Journal of Clinical Investigation. 2026;136(10). doi:10.1172/jci190121
BibTeX
@article{Teh2026,
author = {Teh, Selina Shiqing K and Kotwal, Akhil and Bennett, Alexis and Halper-Stromberg, Eitan and Morsberger, Laura and Zamani, Saum and Shi, Yanan and Skaist, Alyza and Zhu, Qingfeng and Bowland, Kirsten and Liang, Hong and Hruban, Ralph H and Hung, Chien-Fu and Anders, Robert A and Roberts, Nicholas J and Scharpf, Robert B and Goldstein, Michael and Zou, Ying S and Eshleman, James R},
title = {Simultaneous CRISPR/Cas9-induced double-strand breaks are lethal in models of pancreatic cancer},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {10},
doi = {10.1172/jci190121}
}
EUVIMED